Oxfendazole Suppresses Bone Destruction in Preclinical Osteosarcoma Models by Inhibiting ANXA2
Preclinical experiments demonstrate that oxfendazole suppresses osteosarcoma-driven bone destruction by downregulating ANXA2 transcription without directly inhibiting tumor growth.





